BIO-key International, Inc.Find Ratings Reports
BIO-KEY INTERNATIONAL INC's gross profit margin for the fourth quarter of its fiscal year 2020 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the subsector when comparing revenue growth, but not when comparing net income growth. BIO-KEY INTERNATIONAL INC is extremely liquid. Currently, the Quick Ratio is 9.81 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 989.97% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY20||Q4 FY19|
|Net Sales ($mil)||1.06||0.54|
|Net Income ($mil)||-1.44||-9.53|
|Balance Sheet||Q4 FY20||Q4 FY19|
|Cash & Equiv. ($mil)||17.51||0.59|
|Total Assets ($mil)||22.52||2.5|
|Total Debt ($mil)||0.73||2.82|
|Profitability||Q4 FY20||Q4 FY19|
|Gross Profit Margin||82.99||-14.58|
|Return on Assets||-42.95||-584.26|
|Return on Equity||-48.13||0.0|
|Debt||Q4 FY20||Q4 FY19|
|Share Data||Q4 FY20||Q4 FY19|
|Shares outstanding (mil)||7.82||1.8|
|Div / share||0.0||0.0|
|Book value / share||2.6||-1.27|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||356730.0||1127376.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.35 indicates a significant discount versus the S&P 500 average of 4.43 and a significant discount versus the subsector average of 21.30. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average. After reviewing these and other key valuation criteria, BIO-KEY INTERNATIONAL INC proves to trade at a discount to investment alternatives.
|BKYI NM||Peers 65.08||BKYI NM||Peers 64.24|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
BKYI's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
BKYI's P/CF is negative making the measure meaningless.
|BKYI 20.65||Peers 85.96||BKYI NA||Peers 1.57|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
BKYI's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|BKYI 1.35||Peers 21.30||BKYI 61.52||Peers 142.80|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
BKYI is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, BKYI is expected to significantly trail its peers on the basis of its earnings growth rate.
|BKYI 9.66||Peers 15.92||BKYI 25.08||Peers 29.95|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
BKYI is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
BKYI trails its peers on the basis of sales growth.